FOLD - AMICUS THERAPEUTICS, INC.
IEX Last Trade
9.62
-0.030 -0.312%
Share volume: 31,744
Last Updated: Fri 27 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$9.65
-0.03
-0.31%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-07 | 2023-03-01 | 2023-05-10 | 2023-08-08 | 2023-11-08 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 800.589 M | 759.528 M | 724.167 M | 700.519 M | 730.093 M | 764.084 M | 777.880 M | 721.789 M | |
| Current Assets | 497.643 M | 458.539 M | 423.816 M | 399.697 M | 432.822 M | 463.256 M | 483.061 M | 431.239 M | |
| Inventories | 20.879 M | 13.272 M | 23.816 M | 27.004 M | 51.381 M | 56.936 M | 59.696 M | 60.759 M | |
| Other Current Assets | 37.367 M | 38.264 M | 40.209 M | 37.406 M | 52.099 M | 52.689 M | 49.533 M | 54.444 M | |
| Short Term Investments | 37.367 M | 38.264 M | 40.209 M | 37.406 M | 52.099 M | 52.689 M | 49.533 M | 54.444 M | |
| Total Receivables | 52.556 M | 52.303 M | 66.196 M | 68.178 M | 63.716 M | 73.331 M | 87.632 M | 76.433 M | |
| Current Cash | 386.841 M | 354.700 M | 293.595 M | 267.109 M | 265.626 M | 280.300 M | 286.200 M | 239.603 M | |
| Total Non-current Assets | 302.946 M | 300.989 M | 300.351 M | 300.822 M | 297.271 M | 300.828 M | 294.819 M | 290.550 M | |
| Property Plant Equipment | 33.657 M | 32.449 M | 30.778 M | 31.406 M | 30.238 M | 31.072 M | 31.667 M | 32.421 M | |
| Other Assets | 18.045 M | 17.872 M | 19.242 M | 20.172 M | 19.049 M | 21.130 M | 18.553 M | 17.657 M | |
| Intangible Assets | 23.000 M | 23.000 M | 23.000 M | 22.964 M | 22.145 M | 21.318 M | 20.490 M | 19.672 M | |
| Goodwill | 197.797 M | 197.797 M | 197.797 M | 197.797 M | 197.797 M | 197.797 M | 197.797 M | 197.797 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 800.589 M | 759.528 M | 724.167 M | 700.519 M | 730.093 M | 764.084 M | 777.880 M | 721.789 M | |
| Total liabilities | 627.164 M | 626.963 M | 601.120 M | 597.946 M | 618.512 M | 630.847 M | 617.706 M | 591.095 M | |
| Total current liabilities | 164.625 M | 164.650 M | 139.018 M | 138.385 M | 159.235 M | 169.454 M | 167.689 M | 142.102 M | |
| Accounts Payable | 23.113 M | 12.046 M | 15.413 M | 24.965 M | 13.522 M | 23.154 M | 15.120 M | 9.210 M | |
| Other liabilities | 14.113 M | 14.052 M | 13.595 M | 15.554 M | 14.951 M | 14.868 M | 13.282 M | 12.771 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 390.652 M | 391.319 M | 391.990 M | 392.658 M | 393.350 M | 394.071 M | 387.858 M | 388.391 M | |
| Other liabilities | 14.113 M | 14.052 M | 13.595 M | 15.554 M | 14.951 M | 14.868 M | 13.282 M | 12.771 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 173.425 M | 132.565 M | 123.047 M | 102.573 M | 111.581 M | 133.237 M | 160.174 M | 130.694 M | |
| Common stock | 291.971 M | 289.224 M | 286.553 M | 291.337 M | 292.797 M | 295.759 M | 300.765 M | 302.903 M | |
| Retained earnings | -2.443 B | -2.477 B | -2.532 B | -2.585 B | -2.629 B | -2.650 B | -2.684 B | -2.732 B |